The Pro Medicus Ltd (ASX: PME) share price is in focus after addressing speculation of a potential data breach, confirming no client or patient data was accessed and no financial loss occurred.
What did Pro Medicus report?
- Investigated unauthorised access of a single company email inbox in July 2025
- No client systems or patient data were accessed
- No Pro Medicus products, systems, or databases were affected
- No operational impact or financial loss resulted from the incident
- Potential exposure of personal data for approximately 100 current and former employees
- All impacted individuals have been notified
What else do investors need to know?
The company confirmed the cybersecurity incident was isolated to a single mailbox and was quickly contained with the help of external experts. There is no evidence that any commercially sensitive or material information was accessed during the breach.
Pro Medicus has informed all applicable government authorities as required by law, and all directly affected employees were promptly notified about the possible personal data exposure.
What’s next for Pro Medicus?
Pro Medicus states that its systems and client information remain secure. The company continues to review its cybersecurity practices and is committed to protecting data in line with industry best practice.
There is no expectation of financial or operational impact, with Pro Medicus focusing on its ongoing delivery of medical imaging software solutions and services worldwide.
Pro Medicus share price snapshot
Over the past 12 months, Pro Medicus shares have declined 3%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 2% over the same period.
The post Pro Medicus responds to data breach speculation: no client or patient data accessed appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 18 November 2025
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Regis Healthcare sells two QLD homes for $25 million gain
- Bendigo and Adelaide Bank unveils RACQ Bank acquisition in investor update
- 5 things to watch on the ASX 200 on Thursday
- ASX dividend shares: How to snowball your passive income
- These ASX innovators could be the market’s next big winners
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.
Leave a Reply